Sacituzumab goviteca provides clinically meaningful PFS benefit for hormone receptor HR+/HER2‐ advanced breast cancer patients

Ramucirumab plus pembrolizumab improves OS in advanced NSCLC

War in Ukraine: Impacts on the Polish cancer care system and vaccination challenges

Lymphoma Coalition: Challenges for Ukrainian haematological cancer patients

Intratumoral BO-112 with pembrolizumab shows benefit in advanced melanoma refractory to anti-PD-1 therapy

Recurrent non-invasive breast tumours may not always be related to the primary lesion

Novel bispecific checkpoint inhibitor MEDI5752 shows promise for advanced solid tumours

EGFR testing: Best practice for NSCLC patients with exon 20 insertions

Minimal residual disease in multiple myeloma

Preventive oncology nutrition for healthy carriers and BRCA1/2 + breast cancer patients

OncoAlert and ecancer weekly round up for February 7th - 13th, 2022

Update on the new EUSOMA quality indicators for breast cancer